BEDFORD, Mass. — January 21, 2026 — Leads & Copy — Ocular Therapeutix, Inc. has announced the appointment of David W. Robinson as Global Chief Commercial Officer. Robinson, known for his expertise in retina drug launches, previously played a key role in the launch of EYLEA® at Regeneron and recently served as Chief Marketing Officer, Global Ophthalmology at Merck.
The company (NASDAQ: OCUL) said Robinson’s appointment is part of a strategy to prepare for the global launch of AXPAXLI™ (OTX-TKI), a treatment in development for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR), pending approval.
Ocular Therapeutix Executive Chairman, President and CEO Pravin U. Dugel, MD, said Robinson’s experience, particularly with EYLEA, will be invaluable to the company as it advances its NDA timeline and launch preparedness for AXPAXLI.
Robinson will oversee Ocular’s global commercial operations, reporting to Dr. Dugel as part of the Executive Leadership Team. Steve Meyers will remain Chief Commercial Officer, collaborating with Robinson on the AXPAXLI launch plan and continuing to lead marketing for DEXTENZA®.
Robinson said he is excited about AXPAXLI’s potential to improve patient outcomes and simplify treatment logistics, noting its global potential in wet AMD and diabetic retinal disease, with ongoing registrational programs. He sees AXPAXLI as a therapy that can deliver value across the retina ecosystem.
Prior to Ocular, Robinson was responsible for the global launch plan of two new product candidates following Merck’s acquisition of EyeBio. His experience at Regeneron Pharmaceuticals, Inc. includes developing and executing the strategic plan to launch Regeneron’s first product to market, EYLEA® (aflibercept 2 mg).
Robinson also held roles at UCB, Inc., MedImmune Inc., GenVec Inc., and GlaxoSmithKline Inc. He holds a B.S. in Business Administration from Appalachian State University.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on redefining the retina experience with products like AXPAXLI and DEXTENZA®.
AXPAXLI is currently in Phase 3 clinical trials for wet AMD and NPDR. Ocular’s pipeline also includes OTX-TIC, a travoprost intracameral hydrogel for glaucoma or ocular hypertension.
Contact: Bill Slattery, Vice President, Investor Relations, bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
